EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome

Alex E Henney iD, Conor S Gillespiec, Jonathan Y M Lai, Pieta Schofield, David R Riley, Rishi Caleyachetty, Thomas M Barber, Alexander D Miras, Laurence J Dobbie, David M Hughes, Uazman Alam, Theresa J Hydes und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 22.04.2025 · 110 (5) · 1235-1246

DOI: 10.1210/clinem/dgae481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 11.07.2024. Verfasst von Alex E Henney und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool L69 7ZX, UK. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Fatty Liver. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polycystic ovary syndrome (PCOS) is associated with adverse clinical outcomes that may differ according to PCOS phenotype.

Methods

Using UK Biobank data, we compared the incidence of type 2 diabetes (T2D), metabolic dysfunction associated steatotic liver disease, cardiovascular disease (CVD), hormone-dependent cancers, and dementia between PCOS participants and age- and body mass index-matched controls. We also compared multiorgan (liver, cardiac, and brain) magnetic resonance imaging (MRI) data and examined the impact of PCOS phenotype (hyperandrogenic and normoandrogenic) on these outcomes.

Results

We included 1008 women with PCOS (defined by diagnostic codes, self-reported diagnoses, or clinical/biochemical features of hyperandrogenism and a/oligoCmenorrhoea) and 5017 matched controls (5:1 ratio); median age, 61 years, body mass index, 28.4 kg/m². Adjusted Cox proportional hazard modeling demonstrated PCOS participants had greater incident T2D [hazard ratio (HR) 1.47; 95% confidence interval (CI), 1.11-1.95] and all-cause CVD (1.76; 1.35-2.30). No between-group differences existed for cancers or dementia. Liver MRI confirmed more PCOS participants had hepatic steatosis (proton density fat fraction >5.5%: 35.9 vs 23.9%; P = .02) and higher fibroinflammation (corrected T1 721.4 vs 701.5 ms; P = <.01) vs controls. No between-group difference existed for cardiac (biventricular/atrial structure and function) or brain (grey and white matter volumes) imaging. Normoandrogenic (but not hyperandrogenic) PCOS participants had greater incident all-cause CVD (1.82; 1.29-2.56) while hyperandrogenic (but not normoandrogenic) PCOS participants were more likely to have hepatic steatosis (8.96 vs 6.04 vs 5.23%; P = .03) with greater fibroinflammation (776.3 vs 707.7 vs 701.9 ms; P=<.01).

Conclusion

Cardiometabolic disease may be increased in PCOS patients with a disease phenotype-specific pattern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeDiabetes Mellitus, Type 2Cardiovascular DiseasesFatty LiverHumansFemaleMiddle AgedIncidenceAdultUnited KingdomCase-Control StudiesRisk FactorsMagnetic Resonance ImagingDementiaAged

Stichwörter der Autor:innen

cardiovascular diseasehormone-dependent cancersmetabolic dysfunction-associated steatotic liver diseasepolycystic ovary syndrometype 2 diabetes

Autor:innen und Institutionen

  • Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool L69 7ZX, UK.
  • Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside L9 7AL, UK.
  • Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside L69 7ZX, UK.
  • Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 3PT, UK.
  • Department of Public Health, Policy & Systems, University of Liverpool, Liverpool, Merseyside L69 7ZX, UK.
  • Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.

ORCID-Profile: Alex E Henney

Zitieren

APA

Henney, A. E., Gillespiec, C. S., Lai, J. Y. M., Schofield, P., Riley, D. R., Caleyachetty, R., Barber, T. M., Miras, A. D., Dobbie, L. J., Hughes, D. M., Alam, U., Hydes, T. J., & Cuthbertson, D. J. (2025). Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 110(5), 1235-1246. https://doi.org/10.1210/clinem/dgae481

Vancouver

Henney AE, Gillespiec CS, Lai JYM, Schofield P, Riley DR, Caleyachetty R, et al. Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2025;110(5):1235-1246. doi:10.1210/clinem/dgae481

BibTeX
@article{Henney2025,
  author = {Henney, Alex E and Gillespiec, Conor S and Lai, Jonathan Y M and Schofield, Pieta and Riley, David R and Caleyachetty, Rishi and Barber, Thomas M and Miras, Alexander D and Dobbie, Laurence J and Hughes, David M and Alam, Uazman and Hydes, Theresa J and Cuthbertson, Daniel J},
  title = {Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {5},
  pages = {1235--1246},
  doi = {10.1210/clinem/dgae481}
}
Kostenlos starten →